WO2007097934A3 - Methods and compositions for using erythrocytes as carriers for delivery of drugs - Google Patents

Methods and compositions for using erythrocytes as carriers for delivery of drugs Download PDF

Info

Publication number
WO2007097934A3
WO2007097934A3 PCT/US2007/003636 US2007003636W WO2007097934A3 WO 2007097934 A3 WO2007097934 A3 WO 2007097934A3 US 2007003636 W US2007003636 W US 2007003636W WO 2007097934 A3 WO2007097934 A3 WO 2007097934A3
Authority
WO
WIPO (PCT)
Prior art keywords
rbc
drugs
delivery
compositions
provides methods
Prior art date
Application number
PCT/US2007/003636
Other languages
French (fr)
Other versions
WO2007097934A2 (en
Inventor
Elizabeth G Posillico
George L Spitalny
Steven E Pincus
Lihsyng S Lee
Original Assignee
Elusys Therapeutics Inc
Elizabeth G Posillico
George L Spitalny
Steven E Pincus
Lihsyng S Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elusys Therapeutics Inc, Elizabeth G Posillico, George L Spitalny, Steven E Pincus, Lihsyng S Lee filed Critical Elusys Therapeutics Inc
Publication of WO2007097934A2 publication Critical patent/WO2007097934A2/en
Publication of WO2007097934A3 publication Critical patent/WO2007097934A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

The present invention provides methods and compositions for using erythrocyte (RBC) as a carrier for delivery of drugs, e.g., therapeutic enzymes or mammalian serum proteins. The invention involves conjugating the drug to an antibody that binds RBC. When administered to a patient, the RBC binding conjugate binds to RBC, and is delivered to desired locations by the RBC. The invention provides methods of using the RBC binding conjugate for preventing and treating diseases. The invention also provides methods for preparing the RBC binding conjugate.
PCT/US2007/003636 2006-02-17 2007-02-09 Methods and compositions for using erythrocytes as carriers for delivery of drugs WO2007097934A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77489006P 2006-02-17 2006-02-17
US60/774,890 2006-02-17

Publications (2)

Publication Number Publication Date
WO2007097934A2 WO2007097934A2 (en) 2007-08-30
WO2007097934A3 true WO2007097934A3 (en) 2007-11-01

Family

ID=38308689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003636 WO2007097934A2 (en) 2006-02-17 2007-02-09 Methods and compositions for using erythrocytes as carriers for delivery of drugs

Country Status (1)

Country Link
WO (1) WO2007097934A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9475804B2 (en) 2011-06-03 2016-10-25 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9585968B2 (en) 2011-06-03 2017-03-07 3M Innovative Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221236A1 (en) * 2008-12-05 2010-09-02 Satish Singh Mutants of Staphylokinase Carrying Amino and Carboxy-Terminal Extensions for Polyethylene Glycol Conjugation
FR2940087B1 (en) * 2008-12-18 2011-05-06 Lab Francais Du Fractionnement ERYTHROCYTES CONTAINING FACTOR VIII, PREPARATION AND USES.
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
SI2768942T1 (en) 2011-10-17 2020-03-31 Massachusetts Institute Of Technology Intracellular delivery
WO2014063012A1 (en) * 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
JP6502940B2 (en) 2013-08-16 2019-04-17 マサチューセッツ インスティテュート オブ テクノロジー Selective delivery of substances to cells
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3909603A1 (en) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
RU2739794C2 (en) 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Delivery of biomolecules into cells of immune system
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
CA2971626A1 (en) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
AU2016289530B2 (en) 2015-07-09 2021-05-06 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
WO2017126987A1 (en) * 2016-01-18 2017-07-27 Анатолий Викторович ЗАЗУЛЯ Red blood cells for targeted drug delivery
US20180271997A1 (en) * 2016-05-31 2018-09-27 Tianxin Wang Methods and Reagents to Treat Tumor and Cancer
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
CN110279672B (en) * 2019-07-10 2021-07-30 中国科学院苏州纳米技术与纳米仿生研究所 Double-drug-loading erythrocyte carrier, preparation method and application thereof
WO2023169528A1 (en) * 2022-03-11 2023-09-14 西湖生物医药科技(上海)有限公司 Engineered red blood cell targeting pd-1

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705153A (en) * 1992-12-10 1998-01-06 The United States Of America, As Represented By The Department Of Health And Human Services Glycolipid enzyme-polymer conjugates
WO2003063780A2 (en) * 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion
WO2003090695A2 (en) * 2002-04-25 2003-11-06 Transkaryotic Therapies, Inc. TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
WO2004024889A2 (en) * 2002-09-16 2004-03-25 Elusys Therapeutics, Inc. Production of bispecific molecules using polyethylene glycol linkers
US20040127417A1 (en) * 2002-11-20 2004-07-01 Finn Rory F. N-terminally monopegylated human growth hormone conjugates and process for their preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705153A (en) * 1992-12-10 1998-01-06 The United States Of America, As Represented By The Department Of Health And Human Services Glycolipid enzyme-polymer conjugates
WO2003063780A2 (en) * 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion
WO2003090695A2 (en) * 2002-04-25 2003-11-06 Transkaryotic Therapies, Inc. TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
WO2004024889A2 (en) * 2002-09-16 2004-03-25 Elusys Therapeutics, Inc. Production of bispecific molecules using polyethylene glycol linkers
US20040127417A1 (en) * 2002-11-20 2004-07-01 Finn Rory F. N-terminally monopegylated human growth hormone conjugates and process for their preparation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ELIASON J F: "Pegylated cytokines: Potential application in immunotherapy of cancer", BIODRUGS 2001 NEW ZEALAND, vol. 15, no. 11, 2001, pages 705 - 711, XP009088422, ISSN: 1173-8804 *
FRANCIS G E ET AL: "PEGYLATION OF CYTOKINES AND OTHER THERAPEUTIC PROTEINS AND PEPTIDES: THE IMPORTANCE OF BIOLOGICAL OPTIMISATION OF COUPLING TECHNIQUES", INTERNATIONAL JOURNAL OF HEMATOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 68, no. 1, 1998, pages 1 - 18, XP000907109, ISSN: 0925-5710 *
GANGULY KUMKUM ET AL: "Blood clearance and activity of erythrocyte-coupled fibrinolytics.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS MAR 2005, vol. 312, no. 3, March 2005 (2005-03-01), pages 1106 - 1113, XP002447404, ISSN: 0022-3565 *
HOLTSBERG F W ET AL: "Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 80, no. 1-3, 23 April 2002 (2002-04-23), pages 259 - 271, XP004347204, ISSN: 0168-3659 *
MURCIANO J C ET AL: "Tissue-Plasminogen Activator (tPA) Coupling to Erythrocytes Prolongs Its Half-Life and Allows Selective Lysis of Nascent, but Not Pre-Existing Clots", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 100, no. 11, 10 December 2002 (2002-12-10), pages AbstractNo2759, XP009088194, ISSN: 0006-4971 *
VICENT ET AL: "Polymer conjugates: nanosized medicines for treating cancer", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 24, no. 1, January 2006 (2006-01-01), pages 39 - 47, XP005231522, ISSN: 0167-7799 *
WALSH S ET AL: "Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 47, no. 2, February 2003 (2003-02-01), pages 554 - 558, XP002398213, ISSN: 0066-4804 *
ZAITSEV SERGEI ET AL: "Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.", BLOOD 15 SEP 2006, vol. 108, no. 6, 15 September 2006 (2006-09-15), pages 1895 - 1902, XP002447403, ISSN: 0006-4971 *
ZAITSEV SERGEY V ET AL: "Immunotargeting of tissue type plasminogen activator to circulating red blood cells", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 110, no. 17, Suppl s, 10 November 2004 (2004-11-10), pages 149, XP009087870, ISSN: 0009-7322 *
ZALIPSKY S: "FUNCTIONALIZED POLY(ETHYLENE GLYCOL) FOR PREPARATION OF BIOLOGICALLY RELEVANT CONJUGATES", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 6, no. 2, 1995, pages 150 - 165, XP002068523, ISSN: 1043-1802 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9475804B2 (en) 2011-06-03 2016-10-25 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US9585968B2 (en) 2011-06-03 2017-03-07 3M Innovative Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
US9884124B2 (en) 2012-05-17 2018-02-06 Extend Biosciences, Inc. Carriers for improved drug delivery
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates

Also Published As

Publication number Publication date
WO2007097934A2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2007097934A3 (en) Methods and compositions for using erythrocytes as carriers for delivery of drugs
AU2016321431B2 (en) Bioorthogonal compositions
RU2764031C2 (en) Conjugates of antibodies and drugs characterized in high in vivo tolerance
Ezumi et al. Thrombopoietin, c‐Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists‐induced aggregation in platelets in vitro
WO2007113648A3 (en) Ctla4 antibody combination therapy
CN104411329A (en) Compounds for targeted immunotherapy
EA200801570A1 (en) STABLE PROTEIN PREPARATIONS
Chou et al. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
WO2005117952A3 (en) Treatment methods utilizing albumin-binding proteins as targets
WO2012140647A3 (en) Albumin binding probes and drug conjugates thereof
Gong et al. Nanobody‐engineered natural killer cell conjugates for solid tumor adoptive immunotherapy
MX338195B (en) Antibody preparations.
KR20110075054A (en) Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition
EP3560517A2 (en) Aptamer-drug conjugate and use thereof
US20170165334A1 (en) Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
Yasunaga et al. Tailored immunoconjugate therapy depending on a quantity of tumor stroma
US9636419B2 (en) Targeting multiple receptors on a cell surface for specific cell targeting
WO2011053065A3 (en) Catechol polyethylene glycol derivative and protein or peptide conjugates, and method for preparing same
Su et al. New opportunities for immunomodulation of the tumour microenvironment using chemical tools
US20200172905A1 (en) Rna aptamers against transferrin receptor (tfr)
WO2018167795A1 (en) Cannabinoid formulations and dosage
US7101842B2 (en) Targeted delivery of drugs for the treatment of parasitic infections
Ishima et al. Tuning of poly-S-nitrosated human serum albumin as superior antitumor nanomedicine
Mian et al. Development of cirmtuzumab antibody-drug conjugates (ADCs) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07750470

Country of ref document: EP

Kind code of ref document: A2